Clinical significance of defective dendritic cell differentiation in cancer

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1755-1766

  Almand, Bond ^a   Resser, John R ^a   Lindman, Brian ^a   Nadaf, Sorena ^a   Clark, Joseph I ^b   Kwon, Eugene D ^b   Carbone, David P ^a   Gabrilovich, Dmitry I ^b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURGERY; CELL DIFFERENTIATION; DENDRITIC CELL; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL COUNT; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; ENDOTHELIAL GROWTH FACTORS; FLOW CYTOMETRY; GROWTH SUBSTANCES; HUMANS; LYMPH NODES; LYMPHOKINES; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PACLITAXEL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034125451     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Rock, K. L., Rothstein, L., Gamble, S., and Fleischacker, C. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J. Immunol., 150: 438-446, 1993.
2. Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
3. Cozzolino, F., Torcia, M., Carossino, A. M., Giordani, R., Selli, C., Talini, G., Reali, E., Novelli, A., Pistole, V., and Ferrarini, M. Characterization of cells from invaded nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response. J. Exp. Med., 166: 303-318, 1987.
4. Belldegrun, A., Kasid, A., Uppenkamp, M., Topalian, S. L., and Rosenberg, S. A. Human tumor infiltrating lymphocytes: analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J. Immunol., 42: 4520-4526, 1989.
5. Gabrilovich, D., Ciernik, F., and Carbone, D. P. Dendritic cells in anti-tumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol., 170: 101-110, 1996.
6. Thurnher, M., Radmayar, C., Ramoner, R., Ebner, S., Bock, G., Klocker, H., Romani, N., and Bartsch, G. Human renal-cell carcinoma tissue contains dendritic cells. Int. J. Cancer., 67: 1-7, 1996.
7. Nestle, F. O., Burg, G., Fah, J., Wrone-Smith, T., and Nickoloff, B. J. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am. J. Pathol., 750: 641-651, 1997.
8. Chaux, P., Moutet, M., Faivre, J., Martin, F., and M. M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab. Investig., 74: 975-983, 1996.
9. Chaux, P., Favre, N., Martin, M., and M. F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer, 72: 619-624, 1997.
10. Tas, M., Simons, P., Balm, F., and Drexhage, H. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol. Immunother., 36: 108-114, 1993.
11. Gabrilovich, D. I., Corak, J., Ciemik, I. F., Kavanaugh, D., and Carbone, D. P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3: 483-490, 1997.
12. Ishida, T., Oyama, T., Carbone, D., and Gabrilovich, D. I. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hematopoietic progenitors. J. Immunol., 161: 4842-4851, 1998.
13. Gabrilovich, D. I., Nadaf, S., Corak, J., Berzofsky, J. A., and Carbone, D. P. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell. Immunol., 170: 111-120, 1996.
14. Bhardwaj, N., Bender, A., Gonzalez, N., Kim Bui, L., Garrett, M. C., and Steinman, R. M. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. J. Clin. Invest., 94: 797-807, 1994.
15. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., and Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med., 2: 1096-1103, 1996.
16. Menetrier-Caux C., Montmain, G., Dieu, M. C., Bain, C., Favrot, M. C., Caux, C., and Blay, J. Y. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage-colony-stimulating factor. Blood, 92: 4778-4791, 1998.
17. Jasani, B., Navabi, H., Adams, M., Evans, A., and Mason, M. Serum dependent downregulation of CD1a expression and specific CTL priming activity in human dendritic cells. Proc. Am. Assoc. Cancer Res., 30: 611, 1998.
18. Day, G. L., and Blot, W. J. Second primary tumors in patients with oral cancer. Cancer (Phila.), 70: 14-19, 1992.
19. Steinbrink, K., Wolfl, M., Jonuleit, H., Knop, J., and Enk, A. H. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol., 159: 4772-4780, 1997.
20. Huang, R. R., Wen, D-R., Guo, J., Giuliano, A. E., Turner, R., Nguyen, M., Stern, S., and Cochran, A. Modulation of paracortical dendritic cells and T-lymphocytes in breast cancer sentinel nodes. In: 5th International Symposium on Dendritic Cells in Fundamental and Clinical Immunology, p. L16, Pittsburgh, PA, 1998.
21. Gabrilovich, D. I., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., and Carbone, D. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 92: 4150-4166, 1998.
22. Ellis, L. M., and Fidler, I. J. Angiogenesis and metastasis. Eur. J. Cancer, 32A: 2451-2460, 1996.
23. Takano, S., Yoshii, Y., Kondo, S., Suzuki, H., Maruno, T., Shirai, S., and Nose, T. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res., 56: 2185-2190, 1996.
24. Saito, H., Tsujitani, S., Ikeguchi, M., Maeta, M., and Kaibara, N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Bri. J. Cancer, 78: 1573-1577, 1998.
25. Alavena, P., Piemonti, L., Longoni, D., Bernasconi, S., Stoppacciaro, A., Ruco, L., and Mantovani, A. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur. J. Immunol., 28: 359-363, 1998.
26. Peguet Navarro, J., Moulon, C., Caux, C., Dalbiez-Gauthier, C., Banchereau, J., and Schmitt, D. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur. J. Immunol., 24: 884-889, 1994.
27. Enk, A. H., Angeloni, V. L., Udey, M. C., and Katz, S. I. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J. Immunol., 151: 2390-2398, 1993.
28. Beissert, S., Hosoi, J., Grabbe, S., Asahina, A., and Granstein, R. D. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J. Immunol., 154: 1280-1286, 1995.
29. Caux, C., Massacrier, C., Vanbervliet, B., Barthelemy, C., Liu, Y. J., and Banchereau, J. Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. Int. Immunol., 6: 1177-1185, 1994.